People with multiple sclerosis (MS) do not always report their relapses despite the domino effect on their health, financial security and support networks.1 This was most recently confirmed in a UK study published in 2013, which revealed that 46% of respondents experienced a relapse but did not report it, despite considerable impact on their day-to-day lives.1
To better understand how relapse management could be improved, Novartis held a series of focus groups with people with MS and MS healthcare professionals (HCPs).
Some of the key findings from this research are outlined below.
1. Duddy M, Pulfer A, Oswald L. A UK-based study of the impact of relapse in people with relapsing remitting multiple sclerosis (RRMS) early in the course of first disease modifying therapy. Poster presented at ECTRIMS (Congress of the European Committee for Treatment and Research in Multiple Sclerosis) 2013. Multiple Sclerosis Journal. 2013;19(11 Suppl):P590.
2. Duddy M, Pulfer A, Oswald L. A UK-based study of the impact of relapse on clinical decision making early in the course of first-line disease modifying therapy. Multiple Sclerosis Journal. 2013;19(11 Suppl):1035.
3. Hutchinson M. There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion – commentary. Multiple Sclerosis Journal. 2012:18(7):930–931.
Date of preparation: November 2015 MUL15-C020d